Patents Assigned to Osaka Bioscience Institute
-
Patent number: 8658390Abstract: Muscle degenerative diseases can be detected in the early stage and the therapeutic efficacy of a therapeutic agent and/or a therapy method for the diseases can be determined by measuring 11,15-dioxo-9?-hydroxy-2,3,4,5-tetranorprostan-1,20-dioic acid (referred to as “Tetranor-PGDM”, hereinbelow) in a sample isolated from a subject.Type: GrantFiled: March 8, 2010Date of Patent: February 25, 2014Assignees: Osaka Bioscience Institute, National Center of Neurology and Psychiatry, Taiho Pharmaceutical Co., Ltd.Inventors: Yoshihiro Urade, Kosuke Aritake, Toshihiko Maruyama, Shinya Kamauchi, Shin'ichi Takeda, Akinori Nakamura
-
Publication number: 20130005715Abstract: The present invention provides an animal repellent comprising, as an active ingredient, a compound having an odor innately inducing fear in animals, which is free from acclimation of animals to the aforementioned odor. The present invention relates to animal repellent comprising, as an active ingredient, at least one kind selected from a heterocyclic compound represented by the formula (I): wherein ring A is a 3- to 7-membered heterocycle containing at least one hetero atom selected from a nitrogen atom, a sulfur atom and an oxygen atom, and R1 and R2 are each independently hydrogen, a halogen atom, an optionally substituted alkyl group, an optionally substituted alkoxy group, an acyl group, an optionally esterified carboxyl group, an optionally substituted thiol group, an optionally substituted amino group or an oxo group, or a salt thereof, a chain sulfide compound and alkyl isothiocyanate.Type: ApplicationFiled: February 8, 2011Publication date: January 3, 2013Applicants: Scent Science International Inc,., OSAKA BIOSCIENCE INSTITUTEInventors: Ko Kobayakawa, Reiko Kobayakawa
-
Publication number: 20110318764Abstract: Muscle degenerative diseases can be detected in the early stage and the therapeutic efficacy of a therapeutic agent and/or a therapy method for the diseases can be determined by measuring 11,15-dioxo-9?-hydroxy-2,3,4,5-tetranorprostan-1,20-dioic acid (referred to as “Tetranor-PGDM”, hereinbelow) in a sample isolated from a subject.Type: ApplicationFiled: March 8, 2010Publication date: December 29, 2011Applicants: OSAKA BIOSCIENCE INSTITUTE, TAIHO PHARMACEUTICAL CO., LTD., NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRYInventors: Yoshihiro Urade, Kosuke Aritake, Toshihiko Maruyama, Shinya Kamauchi, Shin'ichi Takeda, Akinori Nakamura
-
Publication number: 20100286415Abstract: The invention provides a sleep-improving agent and a sedative agent containing, as an active ingredient, oxypinnatanine or its derivative represented by the following chemical formula (I):Type: ApplicationFiled: May 29, 2008Publication date: November 11, 2010Applicants: OSAKA BIOSCIENCE INSTITUTE, THE DOSHISHA, KUREI OKINAWA CO., LTD.Inventors: Yoshihiro Urade, Zhi-Li Huang, Masashi Wada, Nahoko Uchiyama, Tenji Konishi, Norio Nakamura
-
Patent number: 7760925Abstract: In a method for automatically detecting degenerated regions in many stained thin section specimens (40), color region information is obtained on a degenerated region and on a non-degenerated region on image data of a standard specimen in a stained thin section slide. Next, color region information is obtained on a non-degenerated region on image data of a specimen. Next, the image data of the specimen is compared with the image data of the standard specimen to calculate a color correction quantity to match tone and brightness of the non-degenerated region in the specimen with the counterparts in the non-degenerated region in the standard specimen, and the image data of the specimen is corrected with the color correction quantity. Next, a degenerated region is extracted in the corrected image data of the specimen based on the color region information in the standard specimen.Type: GrantFiled: March 16, 2005Date of Patent: July 20, 2010Assignees: Kurashiki Boseki Kabushiki Kaisha, Osaka Bioscience InstituteInventors: Yasuhisa Sakurai, Hideaki Hikawa, Shuuichi Taneda, Naomi Eguchi
-
Patent number: 7622554Abstract: This invention provides a polypeptide useful in the field of medicines, a DNA which encodes the novel polypeptide, a recombinant DNA molecule which contains the DNA, a transformant transformed with the DNA or the recombinant DNA molecule, a process for the purification of the polypeptide, a process for the production of the polypeptide, an antibody which recognizes the polypeptide, an oligonucleotide complementary to the DNA and a screening method. Particularly this invention provides a polypeptide, which is Fas ligand or a fragment thereof. This polypeptide can be used as an effective ingredient of a medicament for regulating the apoptosis in a living body. This polypeptide is obtained by identifying a DNA fragment, which encodes the polypeptide, transforming a desired host with a recombinant DNA molecule, which contains the DNA fragment, and purifying the polypeptide produced by the resulting transformant.Type: GrantFiled: June 7, 2004Date of Patent: November 24, 2009Assignees: Mochida Pharmaceutical Co., Ltd., Osaka Bioscience InstituteInventors: Shigekazu Nagata, Takashi Suda, Tomohiro Takahashi, Norio Nakamura
-
Patent number: 7399596Abstract: Provided are: a method for predicting the onset of pregnancy-induced hypertension (PIH) by precisely detecting abnormalities that occur before the onset of PIH (where such abnormalities have been impossible to detect by various conventional testing methods for PIH) while imposing less of a burden on a subject; a method for evaluating a fetus and placental functions in PIH; and a method for detecting PIH, which comprises measuring the level of human lipocalin-type prostaglandin D synthase (L-PGDS) in a body fluid sample collected from a subject.Type: GrantFiled: September 24, 2004Date of Patent: July 15, 2008Assignees: Maruha Corporation, Osaka Bioscience InstituteInventors: Hiroshi Oda, Kosuke Seiki, Yasuhiko Shiina, Nobuyuki Sato, Satoru Takeda, Naomi Eguchi, Yoshihiro Urade
-
Patent number: 7314727Abstract: The present invention relates to methods for differentiating demential diseases comprising measuring the concentration of human lipocalin-type prostaglandin D synthase in a sample of a body fluid collected from a subject and kits for differentiating demential diseases comprising an antibody specific to human lipocalin-type prostaglandin D synthase.Type: GrantFiled: June 7, 2001Date of Patent: January 1, 2008Assignees: Maruha Corporation, Japan Science and Technology Corporation, Osaka Bioscience InstituteInventors: Mitsuhito Mase, Hiroya Nakau, Takashi Inui, Naomi Eguchi, Yoshihiro Urade, Kosuke Seiki, Hiroshi Oda, Hiroshi Nakajima, Nobuyuki Sato
-
Patent number: 7238718Abstract: An object of the present invention is to provide a method which is able to prevent or improve the progress of myolytic diseases such as muscular dystrophy. Such an object is able to be solved by a method where an effective dose of an inhibitor for hematopoietic prostaglandin D synthase (H-PGDS) or an antagonist to prostaglandin D receptor is administered to a patient who needs it. The present invention also provides a method for screening compounds which are able to prevent the progress of myolytic diseases and to improve it using human H-PGDS overexpressed transgenic mice.Type: GrantFiled: August 17, 2004Date of Patent: July 3, 2007Assignees: Osaka Bioscience Institute, RikenInventors: Yoshihiro Urade, Naomi Eguchi, Kosuke Aritake, Yo Sato, Masako Taniike, Ikuko Mori, Masashi Miyano
-
Patent number: 7202394Abstract: The present application provides a human gene over-expressing animal, which is a non-human animal carrying a human hematopoietic prostaglandin D2 synthase gene in its somatic cell chromosome and expressing a large amount of human prostaglandin D2 synthase, wherein the animal is one obtained through ontogenesis of a totipotency cell of a non-human animal or offspring of the obtained animal, and the totipotency cell is introduced with said synthase gene. The present application also provides a method of using the transgenic animal for testing in vivo activity of a candidate for anti-allergy medicines, sleep-controlling substances and candidates for anti-obesity.Type: GrantFiled: October 5, 2000Date of Patent: April 10, 2007Assignees: Japan Science and Technology Corporation, Osaka Bioscience Institute, Oriental Yeast Co., Ltd.Inventors: Yoshihiro Urade, Yasushi Fujitani, Hiroaki Kitayama, Naoki Hayashi
-
Publication number: 20060275329Abstract: It is intended to provide a method of diagnosing infection with Chagas disease by screening a trypanocidal drugs for Trypanosoma cruzi which is the pathogen of Chagas disease. Using a flavin protein TcOYE specific to Trypanosoma cruzi, a trypanocidal drugs effective against Trypanosoma cruzi is screened. Using the gene sequence of TcOYE and an antibody therefor, infection with Trypanosoma cruzi is diagnosed.Type: ApplicationFiled: October 10, 2003Publication date: December 7, 2006Applicants: Osaka Bioscience Institute, JAPAN AS REPRESENTED BY THE DIRECTOR-GENERAL OF NATIONAL INSTITUTE OF INFECTIOUS DISEASEInventors: Yoshihiro Urade, Bruno Kubata, Pius Kabututu, Tomoyoshi Nozaki
-
Patent number: 7128905Abstract: The present invention is drawn to methods of preventing and treating diseases wherein the involvement of apoptosis has been indicated.Type: GrantFiled: February 28, 2002Date of Patent: October 31, 2006Assignees: Mochida Pharmaceutical Co., Ltd., Osaka Bioscience InstituteInventors: Shigekazu Nagata, Takehiro Yatomi, Takashi Suda
-
Publication number: 20060089491Abstract: Abstract of the Disclosure This invention provides a novel polypeptide useful in the field of medicines, a novel DNA which encodes the novel polypeptide, a recombinant DNA molecule which contains the novel DNA, a transformant transformed with the novel DNA or the recombinant DNA molecule, a process for the purification of the novel polypeptide, a process for the production of the novel polypeptide, an antibody which recognize the novel polypeptide, an oligonucleotide complementary to the novel DNA and a novel screening method. Particularly this invention provides a novel polypeptide which is Fas ligand or a fragment thereof. This novel polypeptide can be used as an effective ingredient of a medicament for regulating the apoptosis in a living body.Type: ApplicationFiled: June 7, 2004Publication date: April 27, 2006Applicants: Mochida Pharmaceutical Co., Ltd., Osaka Bioscience InstituteInventors: Shigekazu NAGATA, Takashi SUDA, Tomohiro TAKAHASHI, Norio NAKAMURA
-
Publication number: 20050272767Abstract: An object of the present invention is to provide a method which is able to prevent or improve the progress of myolytic diseases such as muscular dystrophy. Such an object is able to be solved by a method where an effective dose of an inhibitor for hematopoietic prostaglandin D synthase (H-PGDS) or an antagonist to prostaglandin D receptor is administered to a patient who needs it. The present invention also provides a method for screening compounds which are able to prevent the progress of myolytic diseases and to improve it using human H-PGDS overexpressed transgenic mice.Type: ApplicationFiled: August 17, 2004Publication date: December 8, 2005Applicant: Osaka Bioscience Institute and RIKENInventors: Yoshihiro Urade, Naomi Eguchi, Kosuke Aritake, Yo Sato, Masako Taniike, Ikuko Mori, Masashi Miyano
-
Publication number: 20050245600Abstract: A novel antimalarial agent. It is a medical composition comprising a pharmaceutically acceptable carrier and a compound represented by the general formula (I), wherein R1 to R12 is independently, hydrogen, halogen, hydroxy, alkyl, alkoxy, amino or acylamino.Type: ApplicationFiled: June 23, 2003Publication date: November 3, 2005Applicant: Osaka Bioscience InstituteInventors: Yoshihiro Urade, Bruno Kubata, Nobutoshi Murakami, Toshihiro Horii
-
Patent number: 6953847Abstract: This invention provides a novel Fas antigen derivative which comprises at least a part or entire portion of Fas antigen extracellular region polypeptide in which at least one amino acid residue is deleted from a group of amino acid residues starting from the N-terminal amino acid residue of the Fas antigen polypeptide to a cysteine residue most close to the N-terminal side (excluding said cysteine residue), as well as a DNA fragment which encodes said Fas antigen derivative, a recombinant DNA molecule which contains said DNA sequence, a transformant in which said recombinant DNA molecule is introduced, a method for the production of said Fas antigen derivative, a medicament which contains said novel Fas antigen derivative as the active ingredient and a method for the improvement of activities and functions of Fas antigen and the like.Type: GrantFiled: September 12, 2001Date of Patent: October 11, 2005Assignees: Mochida Pharmaceutical Co., Ltd., Osaka Bioscience InstituteInventors: Norio Nakamura, Shigekazu Nagata
-
Patent number: 6949360Abstract: DNAs coding for human cell surface antigen (Fas or Fas antigen), vectors for expressing for said DNAs and transformants transfected with said vector are proveded. Fas is a polypeptide that exists in the surfaces of a variety of cells and is considered to be deeply concerned with the apoptosis of cells. The isolated Fas cDNA has an open reading frame that is capable of encoding a protein consisting of 335 amino acids. The mature Fas antigen is a protein consisting of 319 amino acids having a calculated molecular weight of about 36,000 and is constituted by an extracellular domain of 157 amino acids, a membrane-spanning domain of 17 amino acids, and a cytoplasmic domain of 145 amino acids.Type: GrantFiled: June 21, 2001Date of Patent: September 27, 2005Assignee: Osaka Bioscience InstituteInventors: Shigekazu Nagata, Naoto Itoh, Shin Yonehara
-
Method of screening for inhibitors of VCP binding to polyglutamine, abeta, alpha-synuclein, and sod1
Patent number: 6905815Abstract: A method for screening substances which are useful as effective components of prophylactic or therapeutic drug for neurodegenerative diseases caused by the binding of an aberrant protein and a valosin-containing protein, wherein the aberrant protein and the valosin-containing protein and the candidate substance are made to coexist, and the substance that shows inhibitory action on the binding of the aberrant protein and the valosin-containing protein is identified, is provided.Type: GrantFiled: August 24, 2001Date of Patent: June 14, 2005Assignees: Japan Science and Technology Corporation, Osaka Bioscience InstituteInventors: Akira Kakizuka, Miho Hirabayashi -
Patent number: 6897295Abstract: This invention provides a novel polypeptide useful in the field of medicines, a novel DNA which encodes the novel polypeptide, a recombinant DNA molecule which contains the novel DNA, a transformant transformed with the novel DNA or the recombinant DNA molecule, a process for the purification of the novel polypeptide, a process for the production of the novel polypeptide, an antibody which recognizes the novel polypeptide, an oligonucleotide complementary to the novel DNA and a novel screening method. Particularly this invention provides a novel polypeptide which is Fas ligand or a fragment thereof. This novel polypeptide can be used as an effective ingredient of a medicament for regulating the apoptosis in a living body. This novel polypeptide is obtained by identifying a DNA fragment which encodes the novel polypeptide, transforming a desired host with a recombinant DNA molecule which contains the DNA fragment and purifying the novel polypeptide produced by the resulting transformant.Type: GrantFiled: July 16, 1996Date of Patent: May 24, 2005Assignees: Mochida Pharmaceutical Co., Ltd., Osaka Bioscience InstituteInventors: Shigekazu Nagata, Takashi Suda, Tomohiro Takahashi, Norio Nakamura
-
Patent number: 6884819Abstract: The present invention provides a neurodegenerative disease therapeutic agent containing as its active ingredient a (15R)-isocarbacycline derivative indicated by the following formula [I] or a 15-deoxy-isocarbacycline derivative indicated by the following formula [III]: (wherein, R1 represents a C1-C6 alkylene group, and R2 represents a hydrogen atom, a C1-C7, alkyl group or protective group); or, (wherein, R1 and R2 are the same as those defined in formula [I]).Type: GrantFiled: August 4, 2000Date of Patent: April 26, 2005Assignees: Teijin Limited, Osaka Bioscience InstituteInventors: Yorimasa Suwa, Noboru Yoshioka, Takami Arai, Katsutoshi Sakurai, Jun Suzuki, Yasuyoshi Watanabe, Masaaki Suzuki, Takumi Satoh, Yumiko Watanabe, Yosuke Kataoka